跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

VAXON BIOTECH

首页临床试验发起方与机构VAXON BIOTECH

VAXON BIOTECH

52 AV DE L EUROPE, Marly-Le-Roi, Île-de-France, 法国

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

8

6 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

4

50.0%

2 期

1

12.5%

试验状态分布

进行中（未招募）

6

75.0%

已完成

2

25.0%

相关临床试验

该机构主办的试验（8）

Safety Study of Vx006 Vaccine in Solid Tumor Patients

Mar 201423 名受试者

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0201 positive patients with TERT positive NSCLC (stage IV or recurrent stage I-III)

进行中（未招募）

Aug 2013230 名受试者

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0201 positive patients with TERT positive NSCLC (stage IV or recurrent stage I-III)

进行中（未招募）

Aug 2012150 名受试者

Efficacy Study of Vx001 Vaccine in NSCLC Patients

Aug 2012221 名受试者

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0201 positive patients with TERT positive NSCLC (stage IV or recurrent stage I-III)

进行中（未招募）

Feb 2012220 名受试者

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0201 positive patients with TERT positive NSCLC (stage IV or recurrent stage I-III)

进行中（未招募）

Feb 2012220 名受试者

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0201 positive patients with TERT positive NSCLC (stage IV or recurrent stage I-III)

进行中（未招募）

Feb 2012220 名受试者

A multi-centre phase II controlled study of Vx-001 in Non Small Cell Lung Cancer (NSCLC)

进行中（未招募）

Oct 2006225 名受试者

药物批准

暂无批准数据

资讯

Kahimmune Therapeutics Secures Exclusive License for Dark Genome Cancer Vaccine Platform

- Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay for its dark genome-based cancer vaccine platform, targeting previously unexplored non-coding DNA regions. - The company is developing shared mRNA cancer vaccines using novel tumor antigens called Kahigens, with its first candidate KAH-001 targeting colorectal and pancreatic cancers. - A seed funding round is underway with a target of €8 million, with €3 million expected by the end of 2026, as the company advances toward clinical development. - The platform exploits Pioneer Translation Products (PTPs) from non-coding genome regions, potentially offering therapy-specific neoantigens with improved immune recognition compared to conventional approaches.

本页目录

概览
相关临床试验8
药物批准
资讯1

返回机构列表